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ObjectiveaaDISC1 gene is one of the main candidate genes for schizophrenia since it has been associated to the illness in several popu-
lations. Moreover, variations in several DISC1 polymorphisms, and in particular Ser704Cys SNP, have been associated in schizophrenic 
patients to structural and functional modifications in two brain areas (pre-frontal cortex and hippocampus) that play a central role in 
the genesis of psychotic symptoms. This study tested the association between Ser704Cys DISC1 polymorphism and the clinical onset of 
psychosis.
MethodsaaTwo hundred and thirteen Caucasian drug-naïve patients experiencing a first episode of non-affective psychosis were geno-
typed for rs821616 (Ser704Cys) SNP of the DISC1 gene. The clinical severity of the illness was assessed using SAPS and SANS scales. 
Other clinical and socio-demographic variables were recorded to rule out possible confounding effects.
ResultsaaPatients homozygous for the Ser allele of the Ser704Cys DISC1 SNP had significantly (p<0.05) higher rates at the positive 
symptoms dimension (SAPS-SANS scales) and hallucinations item, compared to Cys carriers.
ConclusionaaDISC1 gene variations may modulate the clinical severity of the psychosis at the onset of the disorder. 
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INTRODUCTION
Disrupted-in-Schizophrenia 1 (DISC1) and DISC2 genes 
are located at the breakpoint of a chromosomal translocation 
at 1q42.1 (1;11) (q42.1;q14.3), which was firstly described to 
be linked to major psychiatric disorders, including schizo-
phrenia, in a Scottish family.1 Subsequent studies on different 
ethnic populations provided further evidence supporting the 
role of DISC1 as a susceptibility gene for Schizophrenia spec-
trum disorders.2-12
The biological functions of DISC1 are not completely un-
derstood, and still there is no clear knowledge on how varia-
tions in DISC1 gene could increase the risk of schizophrenia. 
However there is growing evidence regarding the involve-
ment of DISC1 protein in neurodevelopmental processes and 
neural cell signalling through its interaction with the binding 
protein complex known as DISC1 interactome; being FEZ1, 
NEDL1, PDE4, or PSD95 among the proteins included in this 
complex.13,14
During the last decade, the study of the relation between 
DISC1 and different schizophrenia endophenotypes (e.g., 
brain structure and function, cognitive abnormalities), has 
provided evidence of association between variations in sev-
eral DISC1 polymorphisms and brain structure, altered brain 
function and impaired cognitive performance, both in schizo-
phrenic patients and in healthy subjects.4,5,15-22 However, few 
studies have examined the relationship between this gene and 
the clinical presentation in schizophrenia.11,23-25 These studies 
have reported associations between different DISC1 poly-
morphisms and positive psychotic symptoms -hallucinations 
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and delusions-,24,25 as well as psychosis-related traits both in 
schizophrenic patients and in healthy individuals.11,23 Howev-
er none of these studies have examined a sample of first-epi-
sode patients, thus allowing to control the confusion effects 
derived from the treatment and chronicity of the illness.
Among all the numerous DISC1 polymorphisms which 
have been described, the Ser704Cys (rs821616) appears to be 
especially relevant as it has been previously related to different 
aspects of schizophrenia. Specifically, variations in this partic-
ular polymorphism have been associated not only to the risk 
of having schizophrenia,7 but also to several endophenotypes, 
such as brain structural and functional abnormalities,7,15,18 
cognitive impairment,7,17,20 and even clinical presentation.23,25 
All these studies have found that carriers of the Ser allele (or 
Ser/Ser genotype) have an increased risk for showing a higher 
severity of the different abnormalities mentioned above.
The aim of the present study was to examine, in a well-char-
acterized and representative series of patients experiencing a 
first episode of a non-affective psychosis, whether an associa-
tion between DISC1 Ser704Cys polymorphism and clinical 
presentation exists. We hypothesized that carriers of the Ser 
allele (or Ser/Ser genotype) will show a more deleterious ill-
ness onset, with an earlier age of onset and higher psycho-
pathological severity. 
METHODS
The sample for the present study consisted in 213 unrelated 
Caucasian subjects of Spanish origin. The subjects formed 
part of a large prospective longitudinal study on first episode 
non-affective psychosis (PAFIP).26 Those patients referred to 
the program presenting a first episode of non-affective psy-
chosis were admitted to the programme if fulfilling the fol-
lowing criteria: 1.-aged 15-60; 2.-meeting DSM-IV criteria (by 
means of the Structured Clinical Interview for DSM-IV, SCID-
I) 6 months after inclusion for a principal diagnosis of, schizo-
phrenia, schizophreniform disorder, schizoaffective disorder, 
brief reactive psychosis, delusional disorder, or psychosis non 
otherwise specified; 3.-habitually living in the catchment area; 
4.-no prior treatment with antipsychotic medication; and 
5.-current psychotic symptoms of at least moderate severity, 
as assessed by one of the five items of the Scale for the Assess-
ment of Positive Symptoms (SAPS). Patients were not admit-
ted to the programme if presenting any of the following: 
1.-mental retardation; 2.-neurological disorder; or 3.-drug de-
pendence (DSM-IV criteria).
Clinical assessments were carried out with the Scale for the 
Assessment of Positive Symptoms (SAPS),27 Scale for the As-
sessment of Negative Symptoms (SANS),28 and the Clinical 
Global Impression-Severity scale (CGI-S), by a senior psychi-
atrist (BC-F), who was blind to genotype. The positive, nega-
tive and disorganized symptom dimensions were calculated 
from SAPS and SANS scales,29,30 and were used to measure the 
clinical severity of the illness. The positive symptom dimen-
sion is the sum of global scores for the SAPS items hallucina-
tions and delusions. The negative symptom dimension is the 
sum of global scores of the following SANS items: alogia, af-
fective flattening, avolition-apathy, and anhedonia-asociality. 
And the disorganized symptom dimension is the sum of the 
items: positive formal though disorder, disorganized/bizarre 
behaviour, and inappropriate affect.
All subjects gave written informed consent prior to their 
inclusion in the study, which was approved by the local ethics 
committee (University Hospital Marques de Valdecilla Ethics 
Committee).
The control group, which consisted in 303 subjects, was 
obtained from the Blood Bank of the University Hospital 
Marques de Valdecilla. All subjects in the control group gave 
consent for their blood to be genotyped for research purposes. 
Genomic DNA was extracted from peripheral white blood 
cells obtained from each subject according to standard pro-
tocols. The Ser704Cys DISC1 polymorphism–rs821616–was 
genotyped using SNPlex technology (Applied Biosystems, 
Foster City, CA, USA). 
All statistical analyses were carried out using the statistical 
software package SPSS 15.0 for Windows. For the analysis of 
categorical variables, Chi square analyses were carried out. 
For the analyses of the relation between Ser704Cys genotype 
and continuous variables, we used analysis of variance (ANO-
VA) tests. Statistical significance was established at p<0.05.
After completing the association analysis by genotype, and 
in order to facilitate comparison to previous studies, we con-
ducted exploratory analysis of association clustering the pa-
tients into two groups according to being homozygous for the 
Ser allele or carrying the Cys allele.
RESULTS
Gender distribution was 123 males (57.7%) and 90 females 
(42.3%). Mean age of onset in our sample was 27.3 years (SD= 
7.8), higher than what has commonly been reported. The 
mean duration of untreated psychosis (DUP) at initial assess-
ment was 14.5 months (SD=29.4, median=4). 
Among the control group, 177 (59.8%) were male, and 126 
(41.6%) were female. Due to the origin of the control sample, 
sex was the only socio-demographic variable available for the 
current study.
The diagnostic breakdown of the patients was: schizophre-
nia (n=121, 56.8%), schizophreniform disorder (n=52, 24.4%), 
schizoaffective disorder (n=5, 2.3%), brief reactive psychosis 
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(n=18, 8.5%), psychosis not otherwise specified (n=15, 7.0%), 
delusional disorder (n=2, 0.9%).
Patients and controls were in Hardy-Weinberg equilibrium 
for the polymorphism studied. Rs821616 genotypic and allelic 
frequencies were as follow for patients and controls. Patients: 
AA=6.6%; AT=42.7%; TT=50.7% and A=0.28; T=0.72. Con-
trols: AA=8.6%; AT=37%; TT=54.4% and A=0.27; T=0.73.
Gender distribution did not significantly differ between pa-
tients and controls (χ2=0.21; p=0.35). Moreover, gender dis-
tribution both in patients and controls was similar in each of 
the genotype groups (Patients: χ2=3.52; p=0.17; Controls: χ2= 
4.13; p=0.13 respectively). 
Allelic and genotypic distributions were not significantly 
different in patients and controls (Allelic: χ2=0.09; p=0.76; 
Genotypic: χ2=2.04; p=0.36). In the group of patients with 
psychosis, the statistical analyses failed to show any significant 
association between Ser704Cys genotypes and age of onset or 
DUP (Table 1).
When the three commonly used dimensions of psychopa-
thology (positive, negative and disorganised) were analysed, a 
significant association was found between Ser704Cys geno-
type and the positive dimension (Table 2); those patients ho-
mozygous for the Ser allele showed a higher severity of the 
positive dimension than Cys allele carriers (F=6.85; p=0.009) 
(Figure 1). In a further analysis we explored each of the symp-
toms included in the SAPS-SANS positive dimension, finding 
a significant association between Ser704Cys genotype and the 
item hallucinations (F=5.75; p=0.017) following the same di-
rection as the previous result; patients with a Ser/Ser genotype 
showed a mean greater score than Cys carriers (Figure 2).
Table 1. Socio-demographic characteristics of the sample




Mean SD Mean SD Mean SD Mean SD
Age 29.91      7.21 28.65      8.59 28.50   8.48 F=0.17 p=0.84   28.57     8.51 F=0.33 p=0.56
Age of onset 28.19      5.03 27.27      7.95 27.33   7.99 F=0.08 p=0.92 27.3     7.95 F=0.16 p=0.69
DUP (months)   3.91      4.72 16.53   32.97 14.02 27.69 F=1.08 p=0.34   15.17   30.16 F=1.80 p=0.18
N % N % N % N %
Gender (male) 11 78.6 48 52.7 64 59.3 χ2=3.52 p=0.17 112 56.3 χ2=2.66 p=0.08
Diagnostic (6 months-SCID)
Schizophrenia 8 57.1 43 47.3 70 64.8 113 56.8
Schizophreniform Ds 6 42.9 26 28.6 20 18.5 46 23.1
Schizoaffective Ds - - 1   1.1 4    3.7 5   2.5
Others - - 21 22.1 14 13.0 35 17.5
Statistical significance p<0.05. *statistical analysis (chi-square; Anova) for difference between genotype groups, †statistical analysis (chi-square, 
Anova) for difference between genotype groups (Ser/Ser vs. Cys carriers). DUP: Duration of Untreated Psychosis, SAPS: Scale for the assess-
ment of positive symptoms, SANS: Scale for the assessment of negative symptoms, SCID: Structured Clinical Interview for DSM-IV
Table 2. Baseline clinical severity
Ser-Ser (N=14) Ser-Cys (N=91) Cys-Cys (N=108) Statistics* Cys/- (N=199) Statistics†
Mean SD Mean SD Mean SD F p Mean SD F p
SAPS 13.43 3.05 12.79 4.50 13.27 4.57 0.33 0.72 13.05 4.53 0.09 0.76
SANS 5.43 5.59 7.02 5.81 7.23 6.22 0.56 0.57 7.14 6.02 1.06 0.30
Symptom Dimensions
Positive Symptom 8.86 1.83 6.86 2.34 7.42 2.38 4.88 0.009 7.16 2.37 6.85 0.009
Negative Symptom 3.57 3.99 5.30 5.57 5.70 5.85 0.91 0.40 5.52 5.71 1.57 0.21
Disorganized Symptom 4.57 3.34 5.93 3.38 5.85 3.72 0.89 0.41 5.89 3.60 1.76 0.18
Positive symptom  
  dimension’s Items
SAPS Item Hallucinations 3.86 1.83 2.16 2.23 2.53 2.32 3.52 0.031 2.36 2.28 5.75 0.017
SAPS Item Delusions 5.00 0.00 4.69 0.88 4.89 0.34 3.12 0.046 4.80 0.65 1.33 0.25
Statistical significance p<0.05. *analysis of anova for difference between genotype groups, †analysis of anova for difference between genotype 
groups (Ser/Ser vs. Cys carriers). SAPS: Scale for the assessment of positive symptoms, SANS: Scale for the assessment of negative symptoms 
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DISCUSSION
Our study detected a significant association between Ser-
704Cys genotype and severity of positive psychotic symptoms 
in a well-defined Spanish Caucasian population, measured by 
the total score in the SANS-SAPS Positive Symptoms dimen-
sion, and severity of the Hallucinations, at the onset of the ill-
ness. Thus, according to the results, a patient presenting a first 
episode of psychosis and being homozygous for the Ser allele 
will present more likely a worse clinical onset of the illness, 
with more severe positive symptoms and particularly halluci-
nations. 
This finding is consistent with previous reports of an asso-
ciation between carrying the Cys allele and presenting lower 
delusional rating in psychotic patients,25 and lower rates in the 
schizoidia scale in healthy subjects.23
Other studies linked as well clinical presentation to differ-
ent DISC1 polymorphisms; thus Hennah et al.11 described that 
a certain DISC1 haplotype (HEP3) displayed association to 
certain component-traits of Schizophrenia. And similarly an-
other study found an association between the phe allele in leu-
607phe SNP and severity of hallucinations in a sample of Cau-
casian patients with a diagnosis of schizophrenia.24
Moreover, a recent study acknowledged the possibility that 
the severity of the psychosis could be the mediating factor in 
the observed association between a DISC1 rs3738401 variant 
and ultra-resistance to antipsychotic treatment.31
Although DISC1 gene has been postulated as one of the 
main candidate genes for Schizophrenia, to date there is no 
clear evidence supporting the Ser704Cys DISC1 SNP as a risk 
factor for psychosis. While Callicot and colleagues found the 
Ser allele over-transmitted to psychotic patients in a large 
family-based sample,7 a recent study found no association be-
tween this polymorphism and the risk of psychosis.25 In line 
with these results, our study showed no significant association 
between Ser704Cys polymorphism and risk of psychosis in 
the northern Spanish Caucasian population studied.
In addition, when studying the effect of this DISC1 geno-
type on the onset of the illness our study found no association 
between Ser704Cys polymorphism and age of onset or DUP. 
This last result is in agreement with a previous study in a sam-
ple of schizophrenic Japanese patients.42
The biological function of DISC1 is not completely under-
stood, and yet still there is no clear knowledge on how varia-
tions in DISC1 gene could modify the clinical presentation of 
the illness. However, it is today established that DISC1 gene 
encodes for a scaffold protein that interacts with multiple pro-
teins (DISC1 Interactome) involved in neurodevelopment and 
neuro-signalling processes.32-35
DISC1 protein is expressed in neurons in the brain, pre-
dominantly in the hippocampus and cerebral cortex.36 DISC1 
expression has been shown to be lower in patients with Schizo-
phrenia.37 And moreover, those schizophrenic patients Ser ho-
mozygous for Ser704Cys DISC1 polymorphism showed a 
lower expression of some of these partner proteins in these 
brain areas.38
Moreover, Ser/Ser genotype has been associated to a de-
crease in hippocampal grey matter and to abnormal hippo-
campal activity during cognitive tasks.7 And, in healthy subjects 
Ser/Ser genotype showed greater activation of the hippocam-
































Figure 1. Symptom dimensions and Ser704Cys genotypes. Dif-
ferent range of scores for each dimension: Positive dimension: 












Figure 2. Positive symptom dimension and Ser704Cys genotypes.
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ing that these areas needed greater activation to achieve the 
same level of cognitive functioning of those Cys carrier sub-
jects.
Interestingly, these two brain areas -prefontal cortex and 
hippocampus- showing structural and functional changes in 
relation to variations in DISC1 gene, play a central role in the 
genesis of psychotic symptoms according to the dopamine 
theory of Schizophrenia.39,40 Therefore a plausible explanation 
for the involvement of DISC1 in psychosis severity is based 
on its interaction with the dopamine system, perhaps through 
neurodevelopmental modifications in these brain areas de-
rived from DISC1 gene variations which could ultimately 
lead to the functional and structural changes described in 
these two main brain areas as well as differences in clinical se-
verity.
Indeed, a recent review on DISC1details the multiple find-
ings relating DISC1 variations to dopamine system in knock-
down mice and cell studies,41 in line with this explanatory hy-
pothesis.
These results have to be taken into account with caution; the 
study should be replicated in larger samples and other DISC1 
polymorphisms should be included in the study forming hap-
lotypes to obtain a bigger representation of the DISC1 gene.
The sample used in this study, formed by a wide range of 
non-affective psychosis diagnosis might be a caveat in the 
study as the results obtained might be less specific of a core 
schizophrenia diagnosis sub-sample. However, this study 
aimed to identify associations between variations in DISC1 
gene and clinical severity of the onset of psychosis in a wide 
scope, and not in a more restricted sample.
The genotype clustering (Ser homozygous versus Cys carri-
ers) carried out in order to facilitate comparison to previous 
studies, formed two unbalanced groups, which may have in-
fluenced the subsequent statistical analyses, therefore repre-
senting a possible caveat. However, due to the exploratory na-
ture of this analysis we have considered relevant to include it. 
An additional flaw in our study could be the multiple tests 
done. After correcting for multiple testing the statistical sig-
nificance didn’t survive. However this might be explained by 
the sample size and it is likely that in a bigger sample the sta-
tistical significance would have survived multiple testing cor-
rections.
In conclusion, this study showed a significant association 
between DISC1 gene Ser704Cys polymorphism and severity 
of the positive symptoms, in particular hallucinations, at the 
onset of a first episode of psychosis. Therefore, DISC1 gene 
variations may modulate the severity of the psychosis at the 
onset of the illness. 
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